期刊文献+

三七总皂甙对不同时间尿激酶溶栓出血性转化的干预研究 被引量:4

Study of Panax Notoginseng Saponins on Thrombolysis-induced Hemorrhagic Transformation in Rats with Thrombusoccluded Cerebral Ischemia
下载PDF
导出
摘要 目的观察三七总皂甙(PNS)抑制基质金属蛋白酶-9(MMP-9)对大鼠缺血性脑卒中不同时间尿激酶溶栓后血脑屏障破坏和颅内出血性转化的干预效果,探寻减轻溶栓并发症,延长溶栓时间窗的途径。方法采用大鼠自体血栓栓塞大脑中动脉闭塞(MCAO)模型,脑组织中MMP-9表达采用免疫组织化学法,血脑屏障通透性采用伊文氏蓝法,脑出血量的测定采用分光光度计法。结果各时间点尿激酶溶栓组MMP-9表达和脑出血量明显增加,血脑屏障通透性也有增加趋势,随溶栓时间延迟上述指标增加越明显;PNS联合治疗组与单用尿激酶组相应时间点比较MMP-9表达显著下降,血脑屏障通透性和脑出血量均有改善。结论PNS可抑制溶栓后MMP-9高表达,减轻溶栓后血脑屏障破坏和颅内出血性转化,减轻溶栓并发症。 Objective To investigate the effects of panax notoginseng saponms (PNS) on hemorrhage transformation and blood-brain barrier opening. Methods Middle eerehral attery occlusion(MCAO) rats were established by embolizing left middle cerebral artery with autologous blood clots, Tbe expression of matrix metallopeptidasc- 9 (MMP- 9)was detected with immunohistochemieal staining, the permeability of the brain blood barrier was obserw:d with Evan's blue and the cerebral hemorrhage was quantified with spectrophotometer assay. Results MMP - 9 expression,cerebral hemorrhage content and the permeability of the brain -blood barrier were increased with urokinase treatment. And there were obviously increased at more than 6 hour after ischemic stroke. After treatment of urokinase combined with panax notoginseng saponins, the expression of MMP 9 was decreased,and thrombolysis (urokinase)- induced hemorrhage and the brain - blood barrier disruption were reduced. Conclusiun Panax notoginseng saponins could attenuate urokinase - induced the expression of MMP - 9,tbe breakdown of brain blood barri and the cerebral hemorrhage content.
出处 《中西医结合心脑血管病杂志》 2009年第9期1058-1060,共3页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
基金 重庆市卫生局课题(No.04-1-44) 重庆市科委自然科学基金计划资助项目(No.CSTC2006BB5281)
关键词 脑缺血 溶栓治疗 三七总皂甙 基质金属蛋白酶-9 出血性转化 cerebral ischemia tbrombolysis therapy panax notoginseng saponins matrix metalloproteinase - 9 hemorrhage transformation
  • 相关文献

参考文献12

  • 1Harold P, Adams J, Del Zoppo G, et al. Guidelines for the early management of adults wilh ischemic stroke: 2007 AHA/ASA guidelines[J]. Stroke.2007.338(5) : 1655 - 1711.
  • 2Wang XY, Kiyoshi T, Keren L,et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemie stroke[J]. Stroke, 20{11,35 ( 11 ) : 2726 - 2730.
  • 3王文安,周永炜,程洁,王根发,陈兴华.三七皂甙对局灶性脑缺血再灌注后MMP-9表达的影响[J].上海第二医科大学学报,2004,24(9):731-733. 被引量:11
  • 4刘云海,方淑贤.疏血通注射液[J].医药导报,2002,21(6):378-379. 被引量:62
  • 5毛春,邓晓红,张苏明.在改良法血栓栓塞性脑卒中大鼠模型上进行尿激酶静脉溶栓治疗[J].卒中与神经疾病,2003,10(1):20-23. 被引量:10
  • 6Bederson JB,Pitts LH,Tsuji M,et al. Rat middle cerebral artery occlusion:Evaluation ot the model and development of a neurologic examination[J]. Stroke, 1986,17 (:3) : 172 - 476.
  • 7Asahi M,Asahi K,Wang X,et a l. Reduction of tissue plasrninogen activator - induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats [J]. C.ereb Blood Flow Metab,2000,20(3):452- 457.
  • 8Kekky MA, Shuaib A, Todd KG, et al. Matrix metalloproteinase activation and blood brain barrier breakdown following thrombolysis[J]. Exp Neurol,2006,200(4) :38 -49.
  • 9Tsuji K, Aoki T, Tejima E,et al. Tissue plasminogen activator promotes real fix rnetal loproteinase -9 upregulation after focal cerebral ischemia[J]. Stroke,2005,36(9) :1954 - 1959.
  • 10Castellanos M, Sobrino T, Milan M,et al. Serum cellular fibronectin and matrix metalloproteinase - 9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy ill acute ischemic stroke: A multicenter confirmatory study [J]. Stroke,2007,38(6) :1855 - 1859.

二级参考文献15

  • 1韩元岭,陈韬,池国锋.小剂量阿斯匹林、疏血通治疗糖尿病血管病变42例疗效观察[J].心血管康复医学杂志,1999,8(1):41-42. 被引量:3
  • 2谢飞,何思平,张莉.黄芪的药理研究进展[J].云南医药,1994,15(2):157-159. 被引量:19
  • 3汪德清,沈文梅,田亚平,孙仲怡,袁师敏,江朝光.黄芪的三种提取成分对氧自由基作用的影响[J].中国药理学通报,1994,10(2):129-132. 被引量:171
  • 4尹小川,刘建康,周序珑,胡黎平,李朝红,邓漪平.三七总皂甙对培养的猪主动脉内皮细胞释放一氧化氮的影响[J].中国动脉硬化杂志,1996,4(1):20-23. 被引量:26
  • 5刘立岩 刘淑霞 等.疏血通治疗脑梗塞60例临床观察[J].中华实用医学理论与实践,2000,4(1):61-61.
  • 6Fujimura M, Gasche Y, Morita-Fujimura Y, et al. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion [ J].Brain Research 1999, 842:92 - 100.
  • 7Mayer SA, Lignelli A, Fink ME, et al. Perilesional blood flow and edema formation in acute intracerebral hemorrhage: a SPECT study[J]. Stroke, 1998, 29(9): 1 791-1 798.
  • 8del Zoppo GJ, Copeland BR, Anderchek K, et al. Hemorrhagic transformation following tissue plasminogen activator in experimental cerebral infaretion[J]. Stroke,1990, 21: 596 -601.
  • 9Levy DE, Brott TG, Haley EC, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke[ J]. Stroke, 1994,, 25:291 -297.
  • 10Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke [ J ]. Circulation, 2003,107(4): 598 -603.

共引文献84

同被引文献77

引证文献4

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部